Kenichi Ogata1,2, Wataru Katagiri3, Hideharu Hibi1. 1. Department of Oral and Maxillofacial Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan. 2. Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. 3. Department of Oral and Maxillofacial Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan. w-kat@dent.niigata-u.ac.jp.
Abstract
OBJECTIVES: The receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors are novel clinically effective agents that inhibit osteoclast differentiation, function, and survival by binding to RANKL. Medication-related osteonecrosis of the jaw (MRONJ), caused as a result of treatment using denosumab, is a newly emerging type of bone necrosis, the exact pathogenesis of which is unknown. Several studies recently showed that the intravenous administration of mesenchymal stem cells (MSCs) improved the osteonecrosis of the jaw, and it was hypothesized that paracrine effects by secretomes from MSCs are the main constituent. Our aim was to investigate the effects of serum-free conditioned media from human MSCs (MSC-CM) and RANKL inhibitors on osteoclast differentiation. MATERIALS AND METHODS: Cytokines included in MSC-CM were identified using the cytokine array analysis. MSC-CM was added to the culture medium of rat osteoclast precursors containing RANKL inhibitor. Osteoclast differentiation assays, immunohistochemistry, real-time reverse-transcriptase polymerase chain reaction (RT-PCR) analysis, and pit formation assays were performed. RESULTS: MSC-CM included various cytokines such as the recruitment of cell osteogenesis angiogenesis and cell proliferation. MSC-CM promoted osteoclast differentiation and expression of master regulatory transcriptional factors for osteoclastogenesis. In addition, MSC-CM showed function maintenance in osteoclasts despite the presence of RANKL inhibitors. CONCLUSIONS: Our findings suggest that secretomes in MSC-CM were related to the regulation of osteoclast differentiation, which may reduce the effect of RANKL inhibitors. CLINICAL RELEVANCE: New combinations of drugs using factors included in MSC-CM have effective therapeutic modality for treating patients with MRONJ.
OBJECTIVES: The receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors are novel clinically effective agents that inhibit osteoclast differentiation, function, and survival by binding to RANKL. Medication-related osteonecrosis of the jaw (MRONJ), caused as a result of treatment using denosumab, is a newly emerging type of bone necrosis, the exact pathogenesis of which is unknown. Several studies recently showed that the intravenous administration of mesenchymal stem cells (MSCs) improved the osteonecrosis of the jaw, and it was hypothesized that paracrine effects by secretomes from MSCs are the main constituent. Our aim was to investigate the effects of serum-free conditioned media from human MSCs (MSC-CM) and RANKL inhibitors on osteoclast differentiation. MATERIALS AND METHODS: Cytokines included in MSC-CM were identified using the cytokine array analysis. MSC-CM was added to the culture medium of rat osteoclast precursors containing RANKL inhibitor. Osteoclast differentiation assays, immunohistochemistry, real-time reverse-transcriptase polymerase chain reaction (RT-PCR) analysis, and pit formation assays were performed. RESULTS: MSC-CM included various cytokines such as the recruitment of cell osteogenesis angiogenesis and cell proliferation. MSC-CM promoted osteoclast differentiation and expression of master regulatory transcriptional factors for osteoclastogenesis. In addition, MSC-CM showed function maintenance in osteoclasts despite the presence of RANKL inhibitors. CONCLUSIONS: Our findings suggest that secretomes in MSC-CM were related to the regulation of osteoclast differentiation, which may reduce the effect of RANKL inhibitors. CLINICAL RELEVANCE: New combinations of drugs using factors included in MSC-CM have effective therapeutic modality for treating patients with MRONJ.
Authors: Soren Schenk; Niladri Mal; Amanda Finan; Ming Zhang; Matt Kiedrowski; Zoran Popovic; Patrick M McCarthy; Marc S Penn Journal: Stem Cells Date: 2006-10-19 Impact factor: 6.277
Authors: Christoph Pautke; Kilian Kreutzer; Jochen Weitz; Martina Knödler; Daniela Münzel; Gabriele Wexel; Sven Otto; Alexander Hapfelmeier; Stephen Stürzenbaum; Thomas Tischer Journal: Bone Date: 2012-05-07 Impact factor: 4.398
Authors: Paul Humbert; Meadhbh Á Brennan; Noel Davison; Philippe Rosset; Valérie Trichet; Frédéric Blanchard; Pierre Layrolle Journal: Front Immunol Date: 2019-04-02 Impact factor: 7.561
Authors: Sueli Patricia Harumi Miyagi de Cara; Clarice Silvia Taemi Origassa; Fernando de Sá Silva; Maria Stella N A Moreira; Danilo Candido de Almeida; Ana Clara Fagundes Pedroni; Giovanna Lopes Carvalho; Diego Pulzatto Cury; Niels Olsen Saraiva Câmara; Márcia Martins Marques Journal: Heliyon Date: 2019-04-28